These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 25599616)

  • 1. Discovery of 4-(phenyl)thio-1H-pyrazole derivatives as agonists of GPR109A, a high affinity niacin receptor.
    Kim HY; Jadhav VB; Jeong DY; Park WK; Song JH; Lee S; Cho H
    Arch Pharm Res; 2015 Jun; 38(6):1019-32. PubMed ID: 25599616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluorinated pyrazole acids are agonists of the high affinity niacin receptor GPR109a.
    Skinner PJ; Cherrier MC; Webb PJ; Shin YJ; Gharbaoui T; Lindstrom A; Hong V; Tamura SY; Dang HT; Pride CC; Chen R; Richman JG; Connolly DT; Semple G
    Bioorg Med Chem Lett; 2007 Oct; 17(20):5620-3. PubMed ID: 17804224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. beta-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice.
    Walters RW; Shukla AK; Kovacs JJ; Violin JD; DeWire SM; Lam CM; Chen JR; Muehlbauer MJ; Whalen EJ; Lefkowitz RJ
    J Clin Invest; 2009 May; 119(5):1312-21. PubMed ID: 19349687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of pyrazolopyrimidines as the first class of allosteric agonists for the high affinity nicotinic acid receptor GPR109A.
    Shen HC; Taggart AK; Wilsie LC; Waters MG; Hammond ML; Tata JR; Colletti SL
    Bioorg Med Chem Lett; 2008 Sep; 18(18):4948-51. PubMed ID: 18752940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential tissue and ligand-dependent signaling of GPR109A receptor: implications for anti-atherosclerotic therapeutic potential.
    Gaidarov I; Chen X; Anthony T; Maciejewski-Lenoir D; Liaw C; Unett DJ
    Cell Signal; 2013 Oct; 25(10):2003-16. PubMed ID: 23770183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of a biaryl cyclohexene carboxylic acid (MK-6892): a potent and selective high affinity niacin receptor full agonist with reduced flushing profiles in animals as a preclinical candidate.
    Shen HC; Ding FX; Raghavan S; Deng Q; Luell S; Forrest MJ; Carballo-Jane E; Wilsie LC; Krsmanovic ML; Taggart AK; Wu KK; Wu TJ; Cheng K; Ren N; Cai TQ; Chen Q; Wang J; Wolff MS; Tong X; Holt TG; Waters MG; Hammond ML; Tata JR; Colletti SL
    J Med Chem; 2010 Mar; 53(6):2666-70. PubMed ID: 20184326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Future of GPR109A agonists in the treatment of dyslipidaemia.
    Wanders D; Judd RL
    Diabetes Obes Metab; 2011 Aug; 13(8):685-91. PubMed ID: 21418500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression.
    Lauring B; Taggart AK; Tata JR; Dunbar R; Caro L; Cheng K; Chin J; Colletti SL; Cote J; Khalilieh S; Liu J; Luo WL; Maclean AA; Peterson LB; Polis AB; Sirah W; Wu TJ; Liu X; Jin L; Wu K; Boatman PD; Semple G; Behan DP; Connolly DT; Lai E; Wagner JA; Wright SD; Cuffie C; Mitchel YB; Rader DJ; Paolini JF; Waters MG; Plump A
    Sci Transl Med; 2012 Aug; 4(148):148ra115. PubMed ID: 22914621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pyrazole acids as niacin receptor agonists for the treatment of dyslipidemia.
    Schmidt D; Smenton A; Raghavan S; Carballo-Jane E; Lubell S; Ciecko T; Holt TG; Wolff M; Taggart A; Wilsie L; Krsmanovic M; Ren N; Blom D; Cheng K; McCann PE; Gerard Waters M; Tata J; Colletti S
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4768-72. PubMed ID: 19592242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pyrazole derivatives as partial agonists for the nicotinic acid receptor.
    van Herk T; Brussee J; van den Nieuwendijk AM; van der Klein PA; IJzerman AP; Stannek C; Burmeister A; Lorenzen A
    J Med Chem; 2003 Aug; 46(18):3945-51. PubMed ID: 12930155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GPR109a agonists. Part 2: pyrazole-acids as agonists of the human orphan G-protein coupled receptor GPR109a.
    Imbriglio JE; Chang S; Liang R; Raghavan S; Schmidt D; Smenton A; Tria S; Schrader TO; Jung JK; Esser C; Holt TG; Wolff MS; Taggart AK; Cheng K; Carballo-Jane E; Waters MG; Tata JR; Colletti SL
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4472-4. PubMed ID: 20615702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. (1aR,5aR)1a,3,5,5a-Tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalene-4-carboxylic acid (MK-1903): a potent GPR109a agonist that lowers free fatty acids in humans.
    Boatman PD; Lauring B; Schrader TO; Kasem M; Johnson BR; Skinner P; Jung JK; Xu J; Cherrier MC; Webb PJ; Semple G; Sage CR; Knudsen J; Chen R; Luo WL; Caro L; Cote J; Lai E; Wagner J; Taggart AK; Carballo-Jane E; Hammond M; Colletti SL; Tata JR; Connolly DT; Waters MG; Richman JG
    J Med Chem; 2012 Apr; 55(8):3644-66. PubMed ID: 22435740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. beta-Arrestin recruitment assay for the identification of agonists of the sphingosine 1-phosphate receptor EDG1.
    van Der Lee MM; Bras M; van Koppen CJ; Zaman GJ
    J Biomol Screen; 2008 Dec; 13(10):986-98. PubMed ID: 19036707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring β-arrestin recruitment via β-lactamase enzyme fragment complementation: purification of peptide E as a low-affinity ligand for mammalian bombesin receptors.
    Ikeda Y; Kumagai H; Okazaki H; Fujishiro M; Motozawa Y; Nomura S; Takeda N; Toko H; Takimoto E; Akazawa H; Morita H; Suzuki J; Yamazaki T; Komuro I; Yanagisawa M
    PLoS One; 2015; 10(6):e0127445. PubMed ID: 26030739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impedance measurement: a new method to detect ligand-biased receptor signaling.
    Kammermann M; Denelavas A; Imbach A; Grether U; Dehmlow H; Apfel CM; Hertel C
    Biochem Biophys Res Commun; 2011 Sep; 412(3):419-24. PubMed ID: 21827738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-N,N-Disubstituted 5-aminopyrazole-3-carboxylic acids are highly potent agonists of GPR109b.
    Skinner PJ; Webb PJ; Sage CR; Dang TH; Pride CC; Chen R; Tamura SY; Richman JG; Connolly DT; Semple G
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4207-9. PubMed ID: 19524438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Niacin Receptor Agonists: A Promising Strategy for the Treatment of Dyslipidemia.
    Kothawade PB; Thomas AB; Chitlange SS
    Mini Rev Med Chem; 2021; 21(17):2481-2496. PubMed ID: 33550969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of biaryl anthranilides as full agonists for the high affinity niacin receptor.
    Shen HC; Ding FX; Luell S; Forrest MJ; Carballo-Jane E; Wu KK; Wu TJ; Cheng K; Wilsie LC; Krsmanovic ML; Taggart AK; Ren N; Cai TQ; Deng Q; Chen Q; Wang J; Wolff MS; Tong X; Holt TG; Waters MG; Hammond ML; Tata JR; Colletti SL
    J Med Chem; 2007 Dec; 50(25):6303-6. PubMed ID: 17994679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular modeling aided design of nicotinic acid receptor GPR109A agonists.
    Deng Q; Frie JL; Marley DM; Beresis RT; Ren N; Cai TQ; Taggart AK; Cheng K; Carballo-Jane E; Wang J; Tong X; Waters MG; Tata JR; Colletti SL
    Bioorg Med Chem Lett; 2008 Sep; 18(18):4963-7. PubMed ID: 18760600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel treatment target for Parkinson's disease.
    Wakade C; Chong R
    J Neurol Sci; 2014 Dec; 347(1-2):34-8. PubMed ID: 25455298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.